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Learning points for clinicians
• Hepatic autoimmune overlap syndromes should be
considered in patients with evidence of more than one
autoimmune hepatic disease.
• Disease resistant to standard immunosuppression and
treatment of cholestasis can progress rapidly to cirrho-
sis and associated complications.
• Specialist input and treatment with novel therapies,
such as B-cell depleting agents, present an opportunity
to achieve disease remission in refractory cases.
Background
Hepatic overlap syndromes often present with features of auto-
immune hepatitis (AIH) and primary biliary cholangitis (PBC).
Treatment with antiproliferative agents or steroids can prevent
disease progression, but immunosuppression is generally less suc-
cessful in the presence of marked cholestasis. Rituximab has
been used to deplete B cells in a small number of patients with
AIH.1 However, the effects of rituximab in refractory hepatic
overlap syndrome remain unknown, both clinically and
immunologically.
Case presentation
Two sisters with biochemical and histological evidence of AIH/
PBC overlap syndrome were recruited from the hepatology
clinic at the University Hospital of Wales (Table 1). Patient 1
failed to achieve biochemical remission on azathioprine, pred-
nisolone and ursodeoxycholic acid (UDCA). Patient 2 did not tol-
erate azathioprine, prednisolone or UDCA, and was treated
instead with budesonide and mycophenolate mofetil, which
failed to prevent further clinical deterioration. A second liver bi-
opsy demonstrated overlap with progressive fibrosis to early
cirrhosis in Patient 2. Rituximab salvage therapy was com-
menced in both patients, alongside ongoing immunosuppres-
sion. Each patient received a 1 g infusion of rituximab at weeks
0 and 2. Patient 1 also received a 1 g infusion of rituximab at
weeks 52 and 54. Hepatic fine needle aspiration (FNA) was per-
formed using a 22G spinal needle as described previously.2
Peripheral blood and FNA cells were collected prior to rituximab
infusion at weeks 0 and 2. Patient 1 underwent further sampling
at weeks 26, 52 and 54.
Clinical improvement was apparent in both patients, who
reported less fatigue. Serum concentrations of alanine trans-
aminase (ALT), alkaline phosphatase (ALP) and immunoglobu-
lins (IgG and IgM) also fell progressively after treatment
(Figure 1A and B). Lymphocyte subsets were monitored in
parallel using polychromatic flow cytometry. As expected, ritux-
imab therapy induced a rapid loss of peripheral and intrahe-
patic B cells, defined by surface expression of CD19. In Patient 1,
peripheral and intrahepatic B cells emerged again at weeks 26
and 52, but waned to undetectable levels after further doses of
rituximab at weeks 52 and 54 (Figure 1C). Intrahepatic NK cells
were also depleted in Patient 1 (Figure 1D and E). There were no
substantial changes in the phenotypic attributes (data not
shown) or relative frequencies of CD4þ or CD8þ T cells after
rituximab therapy (Figure 1F and G).
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Table 1. Clinical, biochemical and histological characteristics of each patient at diagnosis and before salvage therapy with rituximab
Patient 1 Patient 2
Age 58 62
HLA typing A2, A30, B15 (B62), B18
DR3, DQ2, DQ3, DQB103 (DQ8)
A24, B27, B35
DR4, DR7, DQ2, DQ8
Other autoimmune conditions Type 1 diabetes mellitus
Hypothyroidism
Celiac disease
Antibodies ANA–
SMAþ (1:100)
AMAþ (1:1600)
ANA–
SMAþ (1:25)
AMAþ (1:1600)
ALP (30–150 IU/L) 634 403
ALT (<50 IU/L) 105 204
IgG (6–16 g/L) 19.8 19.2
IgM (0.5–2 g/L) 4.98 8.33
Liver biopsy Interface hepatitis with no fibrosis
Granulomas present with biliary changes
Interface hepatitis with bridging fibrosis
Granulomas present with biliary changes
Established immunosuppression (total daily dose) Azathioprine 100 mg
Prednisolone 10 mg
UDCA 1500 mg
Budesonide 3 mg
Mycophenolate mofetil 2 g
IAIHG score 8 7
Biochemistry pre-rituximab therapy
ALP (30–150 IU/L) 339 243
ALT (<50 IU/L) 54 139
IgG (6–16 g/L) 17.9 12.3
IgM (0.5–2 g/L) 4.06 2.87
Reference values are shown in parentheses for ALP, ALT, IgG and IgM. Titers are shown in parentheses for autoantibodies.
HLA, human leukocyte antigen; ANA, antineutrophil antibody; SMA, smooth muscle antibody; AMA, antimitochondrial antibody; IAIHG, International Autoimmune
Hepatitis Group.
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Figure 1. The response to rituximab infusion (denoted by R) in two sisters with refractory hepatic overlap syndrome. (A) Peripheral blood ALP and ALT levels. Dotted
lines indicate the upper limits of normal. (B) Serum IgG and IgM titers. Dotted lines indicate the upper limits of normal. (C–G) Proportions of intrahepatic and peripheral
blood lymphocyte subsets. (C) B cells. (D) NK cells. (E) CD56dim NK cells. (F) CD4þ T cells. (G) CD8þ T cells.
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Discussion
This is the first report of effective rituximab salvage therapy for
refractory hepatic overlap syndrome. Our data also show that
rituximab can deplete intrahepatic as well as peripheral B cells,
which are thought to perpetuate the disease by presenting auto-
antigens to pathogenic T cells.3
Rituximab depletes B cells via antibody-dependent cellular
cytotoxicity, which is mediated in vitro by CD56dim NK cells.4 In
Patient 1, rituximab therapy coincided with a profound loss of
CD56dim NK cells, potentially reflecting the ongoing use of aza-
thioprine.5 Recrudescent B cells were nonetheless eradicated by
further doses of rituximab, suggesting the existence of additional
depletion mechanisms in the absence of CD56dim NK cells.
Hepatic overlap syndromes are difficult to manage clinically,
especially if standard immunosuppressive regimens are inef-
fective. This report shows that rituximab can arrest refractory
disease. A registry of patients with refractory hepatic auto-
immune and overlap syndromes would facilitate a more sys-
tematic evaluation of long-term outcomes and inform future
randomized clinical trials designed to assess the efficacy of rit-
uximab therapy.
Funding
TPIP is supported by an Academy of Medical Sciences
Starter Grant for Clinical Lecturers and the Ser Cymru II
Programme, which is funded by Cardiff University and the
European Regional Development Fund via the Welsh gov-
ernment. DAP is a Wellcome Trust Senior Investigator.
Conflict of interest: None declared.
References
1.Burak KW, Swain MG, Santodomingo-Garzon T, Lee SS,
Urbanski SJ, Aspinall AI, et al. Rituximab for the treatment of
patients with autoimmune hepatitis who are refractory or in-
tolerant to standard therapy. Can J Gastroenterol 2013; 27:
273–80.
2.Pembroke T, Christian A, Jones E, Hills RK, Wang EC, Gallimore
AM, et al. The paradox of NKp46þ natural killer cells: drivers of
severe hepatitis C virus-induced pathology but in-vivo resist-
ance to interferon alpha treatment. Gut 2014; 63:515–24.
3.Beland K, Marceau G, Labardy A, Bourbonnais S, Alvarez F.
Depletion of B cells induces remission of autoimmune hepa-
titis in mice through reduced antigen presentation and help to
T cells. Hepatology 2015; 62:1511–23.
4.Merkt W, Lorenz HM, Watzl C. Rituximab induces phenotypical
and functional changes of NK cells in a non-malignant experi-
mental setting. Arthritis Res Ther 2016; 18:206.
5.Steel AW, Mela CM, Lindsay JO, Gazzard BG, Goodier MR.
Increased proportion of CD16þ NK cells in the colonic lamina
propria of inflammatory bowel disease patients, but not after
azathioprine treatment. Aliment Pharmacol Ther 2011; 33:
115–26.
0 2
0
10
20
30
26 52 54
CD56dim NK cells
WEEK
%
 o
f l
ym
ph
oc
yt
es
P1 LIVER
P1 BLOOD
P2 LIVER
P2 BLOOD
R R R R
0 2
60
65
70
75
80
85
90
26 52 54
CD4+ T cells
WEEK
%
 o
f l
ym
ph
oc
yt
es
P1 LIVER
P1 BLOOD
P2 LIVER
P2 BLOOD
R R R R
0 2
0
5
10
15
20
25
26 52 54
CD8+ T cells
WEEK
%
 o
f l
ym
ph
oc
yt
es
P1 LIVER
P1 BLOOD
P2 LIVER
P2 BLOOD
R R R R
E F
G
Figure 1. Continued
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